More on IOVA

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (7.5 Score)

Upcoming Events

- Earnings (8/6/21 *Est.)
- Conference (6/17/2021)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Iovance Biotherapeutics (NQ:IOVA)
Delayed: 23.45 +0.31 (1.34%)
Prev. Close $23.14  
Open$23.14 
52 Wk High$ 
52 Wk Low$ 
Day High$23.55 
Day Low$22.05 
P/E N/A  
EPS$ 
Volume6,388,075 

Friends, Peers and Foes (?): CDMOP, CDMO, TCRR, AUTL, RCUS (more...)

Jun 10, 2021 02:00 AM UPDATE: JMP Securities Upgrades Iovanace Biotherapeutics (IOVA) to Market Outperform; Data at ASCO 'Looks Impressive'
Jun 6, 2021 09:24 AM Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Jun 6, 2021 09:24 AM Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Jun 4, 2021 09:09 AM Iovance Biotherapeutics (IOVA) Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO
Jun 4, 2021 09:09 AM Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
Jun 4, 2021 09:08 AM Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting
Jun 1, 2021 07:30 AM Iovance Biotherapeutics to Present at Upcoming Conferences
Jun 1, 2021 07:30 AM Iovance Biotherapeutics to Present at Upcoming Conferences
May 24, 2021 07:09 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $38 at Oppenheimer Seeing CEO Departure Adding Material Risk
May 21, 2021 07:40 AM Iovanace Biotherapeutics (IOVA) PT Lowered to $83 at Goldman Sachs
View All Articles

Entities mentioned with IOVA

View All Entities